Supplementary Table. Relative COVID-19 Vaccine Effectiveness Against Laboratory-Confirmed COVID-19–Associated Hospitalizations and Critical Illness† Among Adults Aged ≥18 Years Who Received a Bivalent Vaccine Dose Compared With Adults Aged ≥18 Years Who Received Monovalent Doses Only, by Age Group and Immunocompromise Status — Seven States, September 2022–April 2023

Details

• Alternative Title:
  Estimates of Bivalent MRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions —VISION Network, September 2022–April 2023: Supplementary Table. Relative COVID-19 Vaccine Effectiveness Against Laboratory-Confirmed COVID-19–Associated Hospitalizations and Critical Illness† Among Adults Aged ≥18 Years Who Received a Bivalent Vaccine Dose Compared With Adults Aged ≥18 Years Who Received Monovalent Doses Only, by Age Group and Immunocompromise Status — Seven States, September 2022–April 2023
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Subjects:
  Disease Notification Public Health Public Health Surveillance
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 21
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  72
• Issue:
  21
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:91a69c1ccc14559d2bc0d066ea9c5927708dde4cefb2267c1199c05ab834022d5aa211652bb113b761522d7befb04a1d9812826f309ab44b6a645541a147cb1d
• Download URL:
  https://stacks.cdc.gov/view/cdc/128421/cdc_128421_DS1.pdf
• File Type:
  [PDF - 154.21 KB ]